文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

胆囊收缩素调节黏膜炎症反应并预防脂多糖诱导的肠上皮屏障功能障碍

Cholecystokinin Modulates the Mucosal Inflammatory Response and Prevents the Lipopolysaccharide-Induced Intestinal Epithelial Barrier Dysfunction.
PubMed 文献 · Shock · 2020-01-01
一句话结论在内毒素血症大鼠中,脂多糖给药前10分钟给予胆囊收缩素0.4 μg/kg或40 μg/kg预处理,可调节黏膜促炎细胞因子产生、增加结肠封闭型紧密连接蛋白表达并减少肠系膜淋巴结细菌计数,作者认为胆囊收缩素可能是有前景的脓毒症激素辅助治疗。

研究在大鼠内毒素血症模型中,于脂多糖给药前10分钟用胆囊收缩素0.4 μg/kg或40 μg/kg预处理,评估黏膜通透性、细菌易位、细胞因子产生、组织学损伤和紧密连接蛋白表达。内毒素血症早期大鼠出现肠屏障功能受损、黏膜通透性增加、细菌易位和炎症反应过度活化。胆囊收缩素预处理调节黏膜促炎细胞因子产生,仅在结肠增加封闭型紧密连接蛋白(occludin、claudin-1和JAM-A)表达,并减少肠系膜淋巴结细菌计数。胆囊收缩素通过CCK-1R在结肠发挥位点特异性作用,该受体经胆囊收缩素处理上调。作者认为胆囊收缩素保护肠黏膜完整性,可能是有前景的脓毒症激素辅助治疗。

要点

  • 在内毒素血症大鼠中,脂多糖给药前10分钟给予胆囊收缩素0.4 μg/kg或40 μg/kg预处理,可调节黏膜促炎细胞因子产生。
  • 胆囊收缩素预处理仅在结肠增加封闭型紧密连接蛋白(occludin、claudin-1和JAM-A)表达。
  • 胆囊收缩素预处理减少肠系膜淋巴结细菌计数,并减轻内毒素血症早期的黏膜通透性增加和细菌易位。
  • 胆囊收缩素通过CCK-1R在结肠发挥位点特异性作用,该受体经胆囊收缩素处理上调。
  • 作者认为胆囊收缩素保护肠黏膜完整性,可能是有前景的脓毒症激素辅助治疗。

适用人群与场景

  • 内毒素血症大鼠(脂多糖给药诱导),在诱导前10分钟接受胆囊收缩素预处理。

处置流程与药物剂量

  • 脂多糖给药前10分钟,大鼠接受胆囊收缩素0.4 μg/kg或40 μg/kg预处理(给药途径原文未写明)。

研究设计与关键结果

  • 研究类型为动物实验(大鼠内毒素血症模型),评估胆囊收缩素0.4 μg/kg或40 μg/kg预处理对黏膜通透性、细菌易位、细胞因子产生、组织学损伤和紧密连接蛋白表达的影响。
  • 内毒素血症早期大鼠出现肠屏障功能受损、黏膜通透性增加、细菌易位和炎症反应过度活化。
  • 胆囊收缩素预处理调节黏膜促炎细胞因子产生,仅在结肠增加封闭型紧密连接蛋白(occludin、claudin-1和JAM-A)表达,并减少肠系膜淋巴结细菌计数。
  • 胆囊收缩素通过CCK-1R在结肠发挥位点特异性作用,该受体经胆囊收缩素处理上调。

证据类型、等级与局限

  • 证据类型:动物实验(大鼠内毒素血症模型)。
  • 作者结论:胆囊收缩素保护肠黏膜完整性,可能是有前景的脓毒症激素辅助治疗。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文为动物实验,作者认为胆囊收缩素可能是有前景的脓毒症激素辅助治疗,未据此给出临床推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

The intestinal mucosa plays a critical role in the organism, acting as an interface between the lamina propria and the harmful antigens in the lumen. Sepsis is associated with primary injury to the intestinal mucosa, which in turn induces bacterial translocation and hyperpermeability. Cholecystokinin (CCK) is a peptide synthesized by several cell types, whose immunomodulatory activity has been reported in experimental models of inflammation. We hypothesized that the CCK treatment could modulate the inflammatory response and protect the integrity of the intestinal barrier in endotoxemic rats. Ten minutes before the endotoxemia induction by lipopolysaccharide (LPS) administration, rats were pretreated with CCK at two doses (0.4 μg/kg or 40 μg/kg). Mucosal permeability, bacterial translocation, cytokines production, histology injury, and expression of tight junction (TJ) proteins were the parameters assessed. In the early phase of endotoxemia, rats exhibited impaired intestinal barrier function, increased mucosal permeability, bacterial translocation, and also hyperactivation of the inflammatory response. On the other hand, the pretreatment with CCK modulated the mucosal production of pro-inflammatory cytokines and increased the expression of seal-forming TJ proteins (occludin, claudin-1 and junctional adhesion molecule (JAM-A)) only in the colon and also, reduced the bacterial counts in the mesenteric lymph nodes. However, CCK has a site-specific mechanism of action in the colon via CCK-1R, which is upregulated by the CCK treatment. In synergy with previous findings from our research group, the present results demonstrated that CCK preserves the integrity of the intestinal mucosa and might be a promising hormonal adjuvant therapy for the treatment of sepsis.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Saia RS, Ribeiro AB, Giusti H, et al. Cholecystokinin Modulates the Mucosal Inflammatory Response and Prevents the Lipopolysaccharide-Induced Intestinal Epithelial Barrier Dysfunction. Shock. 2020. PMID: 30998649. doi:10.1097/SHK.0000000000001355

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。